The Lagos University Teaching Hospital (LUTH), in collaboration with the Sickle Cell Foundation Nigeria (SCFN), has launched a bone marrow transplant program specifically designed for patients with sickle cell disease.
This initiative aligns with international standards, ensuring high-quality and safe transplant procedures in Nigeria.
Sickle cell disease is a major health challenge in Nigeria, one of the countries with the highest prevalence globally. It primarily affects individuals from early childhood, leading to severe health complications.
While current healthcare measures such as newborn screening and chronic blood transfusion therapy have improved survival rates for children, adults still face considerable risks.
The newly established bone marrow transplant program is viewed as a potential cure for sickle cell disease, although it comes with inherent risks, including infections and graft-versus-host disease.
This initiative aims to provide cost-effective treatment options locally, reducing the need for patients to travel abroad for care.
A multidisciplinary team of healthcare professionals has been assembled to support the comprehensive care required for transplant patients.
The programme began its first patient transplants in late August 2024, focusing on meticulous pre-treatment regimens and post-transplant care.
LUTH and SCFN expressed their gratitude to various stakeholders, including patients, families, and partner organizations, for their invaluable support in making this program a reality.
The launch marks a hopeful step toward enhancing the quality of life for individuals affected by sickle cell disease in Nigeria.
